JP7768890B2 - Ｐｈｄ阻害剤化合物、組成物、および使用 - Google Patents

Ｐｈｄ阻害剤化合物、組成物、および使用

Info

Publication number
JP7768890B2
JP7768890B2 JP2022556170A JP2022556170A JP7768890B2 JP 7768890 B2 JP7768890 B2 JP 7768890B2 JP 2022556170 A JP2022556170 A JP 2022556170A JP 2022556170 A JP2022556170 A JP 2022556170A JP 7768890 B2 JP7768890 B2 JP 7768890B2
Authority
JP
Japan
Prior art keywords
compound
formula
alkyl
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022556170A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023518953A (ja
JP2023518953A5 (https=
Inventor
イー． フレミング ポール
ピー． ブライスデル トーマス
ラオ アッル センカラ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akebia Therapeutics Inc
Original Assignee
Akebia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akebia Therapeutics Inc filed Critical Akebia Therapeutics Inc
Publication of JP2023518953A publication Critical patent/JP2023518953A/ja
Publication of JP2023518953A5 publication Critical patent/JP2023518953A5/ja
Priority to JP2025183157A priority Critical patent/JP2026021443A/ja
Application granted granted Critical
Publication of JP7768890B2 publication Critical patent/JP7768890B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2022556170A 2020-03-20 2021-03-19 Ｐｈｄ阻害剤化合物、組成物、および使用 Active JP7768890B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025183157A JP2026021443A (ja) 2020-03-20 2025-10-30 Ｐｈｄ阻害剤化合物、組成物、および使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062992585P 2020-03-20 2020-03-20
US62/992,585 2020-03-20
PCT/US2021/023219 WO2021188936A1 (en) 2020-03-20 2021-03-19 Phd inhibitor compounds, compositions, and use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025183157A Division JP2026021443A (ja) 2020-03-20 2025-10-30 Ｐｈｄ阻害剤化合物、組成物、および使用

Publications (3)

Publication Number Publication Date
JP2023518953A JP2023518953A (ja) 2023-05-09
JP2023518953A5 JP2023518953A5 (https=) 2024-04-01
JP7768890B2 true JP7768890B2 (ja) 2025-11-12

Family

ID=75639962

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022556170A Active JP7768890B2 (ja) 2020-03-20 2021-03-19 Ｐｈｄ阻害剤化合物、組成物、および使用
JP2025183157A Pending JP2026021443A (ja) 2020-03-20 2025-10-30 Ｐｈｄ阻害剤化合物、組成物、および使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025183157A Pending JP2026021443A (ja) 2020-03-20 2025-10-30 Ｐｈｄ阻害剤化合物、組成物、および使用

Country Status (14)

Country Link
US (1) US20230227426A1 (https=)
EP (1) EP4121425A1 (https=)
JP (2) JP7768890B2 (https=)
KR (1) KR20220156889A (https=)
CN (2) CN119823097A (https=)
AR (1) AR121618A1 (https=)
AU (1) AU2021239378A1 (https=)
BR (1) BR112022018877A2 (https=)
CA (1) CA3176140A1 (https=)
CO (1) CO2022014490A2 (https=)
IL (1) IL296631A (https=)
MX (1) MX2022011123A (https=)
TW (1) TW202140443A (https=)
WO (1) WO2021188936A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11713298B2 (en) 2018-05-09 2023-08-01 Akebia Therapeutics, Inc. Process for preparing 2-[[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino]acetic acid
WO2021117767A1 (ja) 2019-12-10 2021-06-17 田辺三菱製薬株式会社 含窒素ヘテロアリールカルボキサミド酢酸誘導体の製造方法
CN115991698B (zh) * 2022-11-03 2024-03-29 广东中科药物研究有限公司 一种杂环化合物及其制备方法与应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008539180A (ja) 2005-04-28 2008-11-13 バイエル・ヘルスケア・アクチェンゲゼルシャフト 心血管および血液疾患の処置用の特異的ｈｉｆ−プロリル−４−ヒドロキシラーゼ阻害剤としての４−（ピリジン−３−イル）−２−（ピリジン−２−イル）−１，２−ジヒドロ−３ｈ−ピラゾール−３−オン誘導体
JP2010507605A (ja) 2006-10-26 2010-03-11 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 置換ジピリジル−ジヒドロピラゾロン類およびそれらの使用
JP2016501882A (ja) 2012-12-06 2016-01-21 クオンティセル ファーマシューティカルズ，インク． ヒストンデメチラーゼ阻害剤
JP2016515582A (ja) 2013-03-29 2016-05-30 武田薬品工業株式会社 ６−（５−ヒドロキシ−１ｈ−ピラゾール−１−イル）ニコチンアミド誘導体およびｐｈｄ阻害剤としてのそれらの使用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008539180A (ja) 2005-04-28 2008-11-13 バイエル・ヘルスケア・アクチェンゲゼルシャフト 心血管および血液疾患の処置用の特異的ｈｉｆ−プロリル−４−ヒドロキシラーゼ阻害剤としての４−（ピリジン−３−イル）−２−（ピリジン−２−イル）−１，２−ジヒドロ−３ｈ−ピラゾール−３−オン誘導体
JP2010507605A (ja) 2006-10-26 2010-03-11 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト 置換ジピリジル−ジヒドロピラゾロン類およびそれらの使用
JP2016501882A (ja) 2012-12-06 2016-01-21 クオンティセル ファーマシューティカルズ，インク． ヒストンデメチラーゼ阻害剤
JP2016515582A (ja) 2013-03-29 2016-05-30 武田薬品工業株式会社 ６−（５−ヒドロキシ−１ｈ−ピラゾール−１−イル）ニコチンアミド誘導体およびｐｈｄ阻害剤としてのそれらの使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ChemMedChem，2018年，Vol. 13, No. 10，p. 988-1003

Also Published As

Publication number Publication date
MX2022011123A (es) 2023-01-04
AU2021239378A1 (en) 2022-11-17
TW202140443A (zh) 2021-11-01
CN115551845A (zh) 2022-12-30
CA3176140A1 (en) 2021-09-23
US20230227426A1 (en) 2023-07-20
CO2022014490A2 (es) 2022-10-21
EP4121425A1 (en) 2023-01-25
JP2023518953A (ja) 2023-05-09
AR121618A1 (es) 2022-06-22
WO2021188936A1 (en) 2021-09-23
CN119823097A (zh) 2025-04-15
KR20220156889A (ko) 2022-11-28
CN115551845B (zh) 2025-02-28
JP2026021443A (ja) 2026-02-10
IL296631A (en) 2022-11-01
BR112022018877A2 (pt) 2022-11-29

Similar Documents

Publication Publication Date Title
JP7768890B2 (ja) Ｐｈｄ阻害剤化合物、組成物、および使用
CN115605467B (zh) Phd抑制剂化合物、组合物和其用途
JP2008523103A (ja) Ｅｒｋプロテインキナーゼのピリミジンインヒビターおよびその使用
US20230159489A1 (en) Phd inhibitor compounds, compositions, and use
JP7832179B2 (ja) Ｐｈｄ阻害剤化合物、組成物、及び使用方法
TWI917364B (zh) Ｐｈｄ抑制劑化合物、組成物及使用方法
BR122025027331A2 (pt) Compostos, composição farmacêutica e uso
JP2025500892A (ja) 選択的ｐｈｄ１阻害剤化合物、組成物、及び使用方法
BR122025027329A2 (pt) Compostos, composição farmacêutica e uso
JP2025500888A (ja) 選択的ｐｈｄ１阻害剤としてのピコリンアミド化合物、組成物、及び使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240318

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250121

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250123

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250416

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250829

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250902

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250926

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251030

R150 Certificate of patent or registration of utility model

Ref document number: 7768890

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150